Hampton, VA

Peninsula Kidney Associates

Chronic Renal Insufficiency

Kidney Diseases

Renal Insufficiency

Chronic Kidney Failure

Atherosclerosis

Hyperphosphatemia

Anemia

Cardiovascular Diseases

Ferric Citrate

Clazakizumab

KRX-0502

Keryx Biopharmaceuticals

Pfizer

Boehringer Ingelheim

CSL Behring

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Peninsula Kidney Associates | Hampton, VA

Site insights

Work at this site?

Active trials

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Trial sponsors